Work

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD

Year: 2025

Type: article

Abstract: ABSTRACT: Until recently, the JAK1/2 inhibitor ruxolitinib (Jakafi) was the only therapy for steroid-refractory acute graft-versus-host disease approved by the US Food and Drug Administration (FDA) for use in patients aged >12 years. The FDA has now approved a potent mesenchymal stromal cell product, remestemcel-L-rknd (Ryoncil), for children aged ≤18 years, showing 70% response rates and ∼70% 6-month survival. In this spotlight, we highlight this important advance in the field.

Source: Blood

DOI: 10.1182/blood.2025028553

Authors: Aaron Etra, James L. M. Ferrara, John E. Levine

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute